Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY

v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2022   194,271      
Beginning balance at Dec. 31, 2022 $ 2,124,261 $ 1,943 $ 2,784,416 $ (652,876) $ (9,222)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 27,460     27,460  
Other comprehensive loss 68       68
Share-based compensation 5,422   5,422    
Stock option exercises (in shares)   327      
Stock option exercises 3,456 $ 3 3,453    
Issuance of common shares in connection with the vesting of restricted stock units (in shares)   310      
Issuances of common stock in connection with the vesting of restricted stock units (102) $ 3 (105)    
Issuance of common stock in connection with a business acquisitions (in shares)   90      
Issuances of common stock in connection with business acquisitions 1,472 $ 1 1,471    
Ending balance (in shares) at Mar. 31, 2023   194,998      
Ending balance at Mar. 31, 2023 $ 2,162,037 $ 1,950 2,794,657 (625,416) (9,154)
Beginning balance (in shares) at Dec. 31, 2023 196,671 196,671      
Beginning balance at Dec. 31, 2023 $ 2,254,112 $ 1,967 2,835,883 (576,813) (6,925)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 24,917     24,917  
Other comprehensive loss (1,667)       (1,667)
Share-based compensation 7,831   7,831    
Stock option exercises (in shares)   46      
Stock option exercises 484   484    
Issuance of common shares in connection with the vesting of restricted stock units (in shares)   627      
Issuances of common stock in connection with the vesting of restricted stock units (876) $ 6 (882)    
Settlement of accrued compensation liabilities through the issuance of common stock (in shares)   1,447      
Settlement of accrued compensation liabilities through the issuance of common stock $ 18,058 $ 15 18,043    
Ending balance (in shares) at Mar. 31, 2024 198,791 198,791      
Ending balance at Mar. 31, 2024 $ 2,302,859 $ 1,988 $ 2,861,359 $ (551,896) $ (8,592)